Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

Data in Brief ◽

10.1016/j.dib.2020.105465 ◽

2020 ◽

Vol 30 ◽

pp. 105465

Author(s):

Bradley J. Monk ◽

Thomas J. Herzog ◽

George Wang ◽

Spyros Triantos ◽

Scott Maul ◽

...

Keyword(s):

Ovarian Cancer ◽

Data Analysis ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Post Hoc

Get full-text (via PubEx)

Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)

Annals of Oncology ◽

10.1093/annonc/mdz250.038 ◽

2019 ◽

Vol 30 ◽

pp. v420-v421

Author(s):

B.J. Monk ◽

T.J. Herzog ◽

S. Triantos ◽

S. Maul ◽

G. Wang ◽

...

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Group Analysis ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Open Label Study ◽

Label Study

Get full-text (via PubEx)

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.12.043 ◽

2020 ◽

Vol 156 (3) ◽

pp. 535-544 ◽

Cited By ~ 5

Author(s):

Bradley J. Monk ◽

Thomas J. Herzog ◽

George Wang ◽

Spyros Triantos ◽

Scott Maul ◽

...

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Multicenter Trial ◽

Open Label ◽

Phase 3 ◽

Safety And Efficacy

Get full-text (via PubEx)

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.001 ◽

2012 ◽

Vol 2012 ◽

pp. 116-117 ◽

Cited By ~ 2

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Multicenter Study ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Efficacy And Safety ◽

Open Label ◽

Polymerase Inhibitor ◽

Brca2 Mutations

Get full-text (via PubEx)

Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications

Epilepsia ◽

10.1111/epi.17092 ◽

2021 ◽

Author(s):

William E. Rosenfeld ◽

Bassel Abou‐Khalil ◽

Sami Aboumatar ◽

Perminder Bhatia ◽

Victor Biton ◽

...

Keyword(s):

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Post Hoc Analysis ◽

Focal Seizures ◽

Post Hoc

Get full-text (via PubEx)

807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.946 ◽

2020 ◽

Vol 31 ◽

pp. S611

Author(s):

K. Omatsu ◽

J. Hamanishi ◽

N. Katsumata ◽

S. Nishio ◽

K. Sawada ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Trial ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Platinum Resistant

Get full-text (via PubEx)

A randomized, open-label study comparing trabectedin and pegylated liposomal doxorubicin with pegylated liposomal doxorubicin alone for the treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer (ET743-OVC-3006)

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.04.035 ◽

2019 ◽

Vol 154 ◽

pp. 12-13 ◽

Cited By ~ 1

Author(s):

B.J. Monk ◽

T.J. Herzog ◽

S. Triantos ◽

G. Wang ◽

W.S.W. Shalaby ◽

...

Keyword(s):

Fallopian Tube ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Open Label ◽

Fallopian Tube Cancer ◽

Open Label Study ◽

Label Study

Get full-text (via PubEx)

An open-label study of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in the Chinese population

Clinical Oncology and Cancer Research ◽

10.1007/s11805-009-0394-2 ◽

2009 ◽

Vol 6 (6) ◽

pp. 394-400

Author(s):

Yang Shen ◽

Zhixiang Shen ◽

Bin Jiang ◽

Jian Hou ◽

Rong Zhan ◽

...

Keyword(s):

Multiple Myeloma ◽

Combination Therapy ◽

Chinese Population ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Newly Diagnosed ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Reduced Dose

Get full-text (via PubEx)

Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies

International Journal of Gynecological Cancer ◽

10.1111/j.1525-1438.2005.00139.x ◽

2005 ◽

Vol 15 (5) ◽

pp. 799-806 ◽

Cited By ~ 8

Author(s):

L.H. LE ◽

K.D. SWENERTON ◽

L. ELIT ◽

D.M. PROVENCHER ◽

G.C.E. STUART ◽

...

Keyword(s):

Phase Ii ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Open Label ◽

Open Label Study ◽

Label Study

Get full-text (via PubEx)

Faculty Opinions recommendation of Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14264100.15777230 ◽

2012 ◽

Author(s):

Sandro Pignata ◽

Sabrina Cecere

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Multicenter Study ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer ◽

Efficacy And Safety ◽

Open Label ◽

Polymerase Inhibitor ◽

Brca2 Mutations

Get full-text (via PubEx)

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2010.05.033 ◽

2010 ◽

Vol 119 (1) ◽

pp. 32-37 ◽

Cited By ~ 163

Author(s):

Michael Friedlander ◽

Kenneth C. Hancock ◽

Danny Rischin ◽

Mark J. Messing ◽

Claude A. Stringer ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Recurrent Ovarian Cancer ◽

Open Label ◽

Open Label Study ◽

Label Study

Get full-text (via PubEx)